253 related articles for article (PubMed ID: 23089527)
21. Design, synthesis and evaluation of novel N-hydroxybenzamides/N-hydroxypropenamides incorporating quinazolin-4(3H)-ones as histone deacetylase inhibitors and antitumor agents.
Hieu DT; Anh DT; Tuan NM; Hai PT; Huong LT; Kim J; Kang JS; Vu TK; Dung PTP; Han SB; Nam NH; Hoa ND
Bioorg Chem; 2018 Feb; 76():258-267. PubMed ID: 29223029
[TBL] [Abstract][Full Text] [Related]
22. Quinazoline-Based Hydroxamic Acids: Design, Synthesis, and Evaluation of Histone Deacetylase Inhibitory Effects and Cytotoxicity.
Hieu DT; Anh DT; Hai PT; Huong LT; Park EJ; Choi JE; Kang JS; Dung PTP; Han SB; Nam NH
Chem Biodivers; 2018 Jun; 15(6):e1800027. PubMed ID: 29667768
[TBL] [Abstract][Full Text] [Related]
23. An Endogenous Reactive Oxygen Species (ROS)-Activated Histone Deacetylase Inhibitor Prodrug for Cancer Chemotherapy.
Bhagat SD; Singh U; Mishra RK; Srivastava A
ChemMedChem; 2018 Oct; 13(19):2073-2079. PubMed ID: 30070768
[TBL] [Abstract][Full Text] [Related]
24. A cyclodextrin-capped histone deacetylase inhibitor.
Amin J; Puglisi A; Clarke J; Milton J; Wang M; Paranal RM; Bradner JE; Spencer J
Bioorg Med Chem Lett; 2013 Jun; 23(11):3346-8. PubMed ID: 23591111
[TBL] [Abstract][Full Text] [Related]
25. Investigation of the effect of different linker chemotypes on the inhibition of histone deacetylases (HDACs).
Linciano P; Benedetti R; Pinzi L; Russo F; Chianese U; Sorbi C; Altucci L; Rastelli G; Brasili L; Franchini S
Bioorg Chem; 2021 Jan; 106():104462. PubMed ID: 33213894
[TBL] [Abstract][Full Text] [Related]
26. The mechanism of the anti-tumor activity of the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA).
Marks PA
Cell Cycle; 2004 May; 3(5):534-5. PubMed ID: 15020838
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and Anti-tumor Activities of Novel Phenyl Substituted Suberoylanilide Hydroxamic Acid Derivatives Against Human Cancer Cells.
Xie R; Shi J; Qu Y; Tang P; Wu X; Yang M; Yuan Q
Med Chem; 2015; 11(7):636-48. PubMed ID: 25922175
[TBL] [Abstract][Full Text] [Related]
28. Design, synthesis and preliminary bioactivity studies of 1,3,4-thiadiazole hydroxamic acid derivatives as novel histone deacetylase inhibitors.
Guan P; Sun F; Hou X; Wang F; Yi F; Xu W; Fang H
Bioorg Med Chem; 2012 Jun; 20(12):3865-72. PubMed ID: 22579621
[TBL] [Abstract][Full Text] [Related]
29. The discovery of colchicine-SAHA hybrids as a new class of antitumor agents.
Zhang X; Zhang J; Tong L; Luo Y; Su M; Zang Y; Li J; Lu W; Chen Y
Bioorg Med Chem; 2013 Jun; 21(11):3240-4. PubMed ID: 23602523
[TBL] [Abstract][Full Text] [Related]
30. SAHA Capture Compound--a novel tool for the profiling of histone deacetylases and the identification of additional vorinostat binders.
Fischer JJ; Michaelis S; Schrey AK; Diehl A; Graebner OY; Ungewiss J; Horzowski S; Glinski M; Kroll F; Dreger M; Koester H
Proteomics; 2011 Oct; 11(20):4096-104. PubMed ID: 21898820
[TBL] [Abstract][Full Text] [Related]
31. Phosphorus containing analogues of SAHA as inhibitors of HDACs.
Pun MD; Wu HH; Olatunji FP; Kesic BN; Peters JW; Berkman CE
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1315-1319. PubMed ID: 35514164
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and evaluation of aliphatic-chain hydroxamates capped with osthole derivatives as histone deacetylase inhibitors.
Huang WJ; Chen CC; Chao SW; Yu CC; Yang CY; Guh JH; Lin YC; Kuo CI; Yang P; Chang CI
Eur J Med Chem; 2011 Sep; 46(9):4042-9. PubMed ID: 21712146
[TBL] [Abstract][Full Text] [Related]
33. Carbamates as Potential Prodrugs and a New Warhead for HDAC Inhibition.
King K; Hauser AT; Melesina J; Sippl W; Jung M
Molecules; 2018 Feb; 23(2):. PubMed ID: 29393896
[TBL] [Abstract][Full Text] [Related]
34. Novel Suberoylanilide Hydroxamic Acid Analogs Inhibit Angiogenesis and Induce Apoptosis in Breast Cancer Cells.
Moku G; Vangala S; Yakati V; Gali CC; Saha S; Madamsetty VS; Vyas A
Anticancer Agents Med Chem; 2022; 22(5):914-925. PubMed ID: 34488592
[TBL] [Abstract][Full Text] [Related]
35. Amide-based derivatives of β-alanine hydroxamic acid as histone deacetylase inhibitors: attenuation of potency through resonance effects.
Liao V; Liu T; Codd R
Bioorg Med Chem Lett; 2012 Oct; 22(19):6200-4. PubMed ID: 22932316
[TBL] [Abstract][Full Text] [Related]
36. Design and synthesis of novel histone deacetylase inhibitor derived from nuclear localization signal peptide.
Canzoneri JC; Chen PC; Oyelere AK
Bioorg Med Chem Lett; 2009 Dec; 19(23):6588-90. PubMed ID: 19854643
[TBL] [Abstract][Full Text] [Related]
37. In silico modification of suberoylanilide hydroxamic acid (SAHA) as potential inhibitor for class II histone deacetylase (HDAC).
Tambunan US; Bramantya N; Parikesit AA
BMC Bioinformatics; 2011; 12 Suppl 13(Suppl 13):S23. PubMed ID: 22373132
[TBL] [Abstract][Full Text] [Related]
38. Design, synthesis and preliminary bioactivity studies of 1,2-dihydrobenzo[d]isothiazol-3-one-1,1-dioxide hydroxamic acid derivatives as novel histone deacetylase inhibitors.
Han L; Wang L; Hou X; Fu H; Song W; Tang W; Fang H
Bioorg Med Chem; 2014 Mar; 22(5):1529-38. PubMed ID: 24525003
[TBL] [Abstract][Full Text] [Related]
39. Antibody drug conjugates with hydroxamic acid cargos for histone deacetylase (HDAC) inhibition.
Cianferotti C; Faltoni V; Cini E; Ermini E; Migliorini F; Petricci E; Taddei M; Salvini L; Battistuzzi G; Milazzo FM; Anastasi AM; Chiapparino C; De Santis R; Giannini G
Chem Commun (Camb); 2021 Jan; 57(7):867-870. PubMed ID: 33433550
[TBL] [Abstract][Full Text] [Related]
40. Potent and selective inhibition of histone deacetylase 6 (HDAC6) does not require a surface-binding motif.
Wagner FF; Olson DE; Gale JP; Kaya T; Weïwer M; Aidoud N; Thomas M; Davoine EL; Lemercier BC; Zhang YL; Holson EB
J Med Chem; 2013 Feb; 56(4):1772-6. PubMed ID: 23368884
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]